Preferentially Expressed Antigen in Melanoma (PRAME) Peptide
-
- Target See all PRAME products
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
- Peptide Type
- Synthetic
- Origin
- Mammalian
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Sequence
- AMVQAWPFTC LPLGVLMKGQ HLHLETFKAV LDGLDVLLAQ EVRPRRWKLQ
- Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of PRAME antibody,
Alternative Names: PRAME control peptide, PRAME antibody Blocking Peptide, Anti-PRAME Blocking Peptide, Preferentially Expressed Antigen In Melanoma Blocking Peptide, MAPE Blocking Peptide, OIP4 Blocking Peptide
-
-
- Application Notes
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Store at -20 °C long term.
-
- Target
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
- Synonyms
- PRAME Peptide, CT130 Peptide, MAPE Peptide, OIP-4 Peptide, OIP4 Peptide, 4930534P07Rik Peptide, preferentially expressed antigen in melanoma Peptide, PRAME Peptide, Prame Peptide
- Background
- PRAME functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. PRAME prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.
- Molecular Weight
- 56 kDa
-